Yeah if you can buy it, buy it, I guess ... but for those having built it, well, some (or many) will leave, onto other, fresher pastures: once an entrepreneur always an entrepreneur.
I sure don't miss the bureaucracy that goes along with a 2,000 person company. 20 employees is better.
I posted this WSJ Pharmalot piece a while back but maybe you didn't see. Merck granting incredibly favorable terms to NGM ... If only CTIX could strike such a sweetheart deal. Liked the little guys redefinition of the Golden Rule.
I think what makes this deal somewhat unusual is that we are able to retain the autonomy to pursue various discovery stage programs at our discretion.
You’re familiar with the golden rule? He who brings the gold, makes the rule. In this case, Merck is trying, in essence, not to stifle this innovative culture without being too prescriptive or officious about what we should be working on. I think this distinguishes the deal from these contract research-type deals where the big company tells the little company what to work on. We can lead R&D up to proof of concept. And after proof of concept, Merck has the ability to exercise an option to license that program. So at that point, they would run it… We have the latitude to move into other therapeutic areas.
Xxxxxxx
F1ash - yeah maybe Merck has a bit of buyer's remorse---coulda shoulda woulda, like someday AbbVie might for PCYC perhaps? (Personally AbbVie might be a good fit for CTIX at some pt... See links below). And maybe Merck is eyeing that other Mass-based company. Who knows. But given the activity (need, incentives) in the ABX sector it's just a matter of time before CTIX, with its next gen class of compounds, announces a deal.
News 
Market Data 
Discover 
